Stockreport

ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study [Yahoo! Finance]

Zenas BioPharma, Inc.  (ZBIO) 
PDF Data from the same showed that treatment with obexelimab led to a highly statistically significant and clinically meaningful 56% reduction in the risk of IgG4-RD flare [Read more]